Mesenchymal stromal cells in the treatment of pediatric hematopoietic cell transplantation-related complications (graft vs. host disease, hemorrhagic cystitis, graft failure and poor graft function) : a single center experience
Pérez-Torres Lobato, Maria (Vall d'Hebron Institut d'Oncologia)
Benítez Carabante, Maria Isabel (Vall d'Hebron Institut d'Oncologia)
Alonso, Laura (Vall d'Hebron Institut d'Oncologia)
Torrents, Silvia (Banc de Sang I Teixits)
Castillo Flores, Nerea (Banc de Sang I Teixits)
Uria Oficialdegui, Maria Luz (Vall d'Hebron Institut d'Oncologia)
Panesso, Melissa (Vall d'Hebron Institut d'Oncologia)
Alonso-Martínez, Carla (Hospital Universitari Vall d'Hebron)
Oliveras, Maria (Hospital Universitari Vall d'Hebron)
Renedo-Miró, Berta (Hospital Universitari Vall d'Hebron)
Vives Armengol, Joaquim (Vall d'Hebron Institut d'Oncologia)
Díaz de Heredia, Cristina (Vall d'Hebron Institut d'Oncologia)
Universitat Autònoma de Barcelona

Data:	2024
Resum:	To describe mesenchymal stromal cells (MSCs) in the treatment of hematopoietic stem cell transplantation (HSCT) complications and to assess its safety and efficacy. Single-center retrospective study (2016-2023). Patients under 20 years who received MSCs for the treatment of HSCT-related complications were included. Thirty patients (53. 7% boys), median age at transplant 11 years (range 2-19) were included. MSCs indications were: graft-vs. -host disease (GVHD) in 18 patients (60%), of them 13 had acute GVHD (43. 3%) and 5 chronic GVHD (16. 7%); Grade 3-4 hemorrhagic cystitis (HC) in 4 (13. 3%); poor graft function (PGF) in 6 (20%), 5 of them receiving MSCs with a CD34 stem cell-boost coinfusion; graft failure (GF) in 2 (6. 7%), to enhance engraftment after a subsequent HSCT. Infusion-related-adverse-events were not reported. Overall response (OR) was 83% (25/30); 44% of responders (11/25) showed complete response (CR). OR for GVHD, HC, PGF and GF was 83. 3%, 100%, 66. 7% and 100% respectively. Response rate was 40% (95% CI: 20-55) and 79% (95% CI: 57-89) at 15 and 30 days. With a median follow-up of 21 months (IQR11-52. 5), overall survival (OS) was 86% (95% CI: 74-100) and 79% (95% CI: 65-95) at 6 and 12 months post-MSCs infusion. In our study, the most frequent indication of MSCs was refractory aGVHD (43. 3%). Response rates were high (OR 83%) and safety profile was good.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Children ; Graft failure ; Graft vs. host disease ; Hematopoietic stem cell transplantation ; Hemorrhagic cystitis ; Mesenchymal stromal cells ; Poor graft function
Publicat a:	Frontiers in Pediatrics, Vol. 12 (2024) , p. 1375493, ISSN 2296-2360

DOI: 10.3389/fped.2024.1375493
PMID: 38783918

10 p, 629.1 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats